Novel cancer therapeutics with allosteric modulation of the mitochondrial C-Raf-DAPK complex by Raf inhibitor combination therapy

Cancer Research

Volumn 75, Issue 17, 2015, Pages 3568-3582

  Tsai, Yi Ta ^a,b   Chuang, Mei Jen ^b   Tang, Shou Hung ^b   Wu, Sheng Tang ^b   Chen, Yu Chi ^c   Sun, Guang Huan ^a,b   Hsiao, Pei Wen ^d   Huang, Shih Ming ^a   Lee, Hwei Jen ^a   Yu, Cheng Ping ^a,b   Ho, Jar Yi ^a,b   Lin, Hui Kuan ^e,f   Chen, Ming Rong ^a,b   Lin, Chung Chih ^b   Chang, Sun Yran ^b,g   Lin, Victor C ^c   Yu, Dah Shyong ^a,b   Cha, Tai Lung ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c E DA HOSPITAL   (Taiwan)

^d AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; DEATH ASSOCIATED PROTEIN KINASE; RAF PROTEIN; SORAFENIB; 5-IODO-3-((3,5-DIBROMO-4-HYDROXYPHENYL)METHYLENE)-2-INDOLINONE; CARBANILAMIDE DERIVATIVE; DAPK1 PROTEIN, HUMAN; INDOLE DERIVATIVE; NICOTINAMIDE; PHENOL DERIVATIVE; REACTIVE OXYGEN METABOLITE;

ALLOSTERISM; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER PROGNOSIS; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE FREE SURVIVAL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MITOCHONDRION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; AGED; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENE INACTIVATION; GENETICS; KIDNEY NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

AGED; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DEATH-ASSOCIATED PROTEIN KINASES; DISEASE-FREE SURVIVAL; DRUG SYNERGISM; FEMALE; GENE KNOCKOUT TECHNIQUES; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MICE; MIDDLE AGED; MITOCHONDRIA; NIACINAMIDE; PHENOLS; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-RAF; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942862279     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3264     Document Type: Article

References (49)

1. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996;87:629-38.
2. Alavi A, Hood JD, Frausto R, StupackDG, Cheresh DA.Role of Raf invascular protection from distinct apoptotic stimuli. Science 2003;301:94-6.
3. Galmiche A, Fueller J, Santel A, Krohne G, Wittig I, Doye A, et al. Isoformspecific interaction of C-RAF with mitochondria. J Biol Chem 2008;283: 14857-66.
4. Campello S, Lacalle RA, Bettella M, Manes S, Scorrano L, Viola A. Orchestration of lymphocyte chemotaxis by mitochondrial dynamics. J Exp Med 2006;203:2879-86.
5. Szabadkai G, Simoni AM, Bianchi K, De Stefani D, Leo S, Wieckowski MR, et al. Mitochondrial dynamics and Ca2+ signaling. Biochim Biophys Acta 2006;1763:442-9.
6. Alirol E, Martinou JC. Mitochondria and cancer: is there a morphological connection? Oncogene 2006;25:4706-16.
7. O'Neill E, Rushworth L, Baccarini M, Kolch W. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 2004;306:2267-70.
8. Le Mellay V, Houben R, Troppmair J, Hagemann C, Mazurek S, Frey U, et al. Regulation of glycolysis by Raf protein serine/threonine kinases. Adv Enzyme Regul 2002;42:317-32.
9. Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha andMITF. Cancer Cell 2013;23:302-15.
10. Zebisch A, Troppmair J. Back to the roots: the remarkable RAF oncogene story. Cell Mol Life Sci 2006;63:1314-30.
11. Troppmair J, Bruder JT, Munoz H, Lloyd PA, Kyriakis J, Banerjee P, et al. Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol- 13-acetate requires Raf and is necessary for transformation. J Biol Chem 1994;269:7030-5.
12. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011;364:772-4.
13. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-5.
14. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140:209-21.
15. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-30.
16. Cohen O, Feinstein E, Kimchi A. DAP-kinase is a Ca2+/calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J 1997;16:998-1008.
17. Jang CW, Chen CH, Chen CC, Chen JY, Su YH, Chen RH. TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. NatCell Biol 2002;4:51-8.
18. Inbal B, CohenO, Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach L, et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997; 390:180-4.
19. Eisenberg-Lerner A, Kimchi A. DAP kinase regulates JNK signaling by binding and activating protein kinase D under oxidative stress. Cell Death Differ 2007;14:1908-15.
20. Widau RC, Jin Y, Dixon SA, Wadzinski BE, Gallagher PJ. Protein phosphatase 2A (PP2A) holoenzymes regulate death-associated protein kinase (DAPK) in ceramide-induced anoikis. J Biol Chem 2010;285:13827-38.
21. Guenebeaud C, Goldschneider D, Castets M, Guix C, Chazot G, Delloye- Bourgeois C, et al. The dependence receptor UNC5H2/B triggers apoptosis via PP2A-mediated dephosphorylation of DAP kinase. Mol Cell 2010; 40:863-76.
22. Lin Y, Hupp TR, Stevens C. Death-associated protein kinase (DAPK) and signal transduction: additional roles beyond cell death. FEBS J 2010; 277:48-57.
23. Wang WJ, Kuo JC, Ku W, Lee YR, Lin FC, Chang YL, et al. The tumor suppressor DAPK is reciprocally regulated by tyrosine kinase Src and phosphatase LAR. Mol Cell 2007;27:701-16.
24. Chen CH, Wang WJ, Kuo JC, Tsai HC, Lin JR, Chang ZF, et al. Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK. EMBO J 2005;24:294-304.
25. Michie AM, McCaigAM, Nakagawa R, VukovicM. Death-associated protein kinase (DAPK) and signal transduction: regulation in cancer. FEBS J 2010; 277:74-80.
26. Liu Y, Gao W, Siegfried JM, Weissfeld JL, Luketich JD, Keohavong P. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. BMC Cancer 2007;7:74.
27. Niklinska W, Naumnik W, Sulewska A, Kozlowski M, Pankiewicz W, Milewski R. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Folia Histochem Cytobiol 2009;47:275-80.
28. Christoph F, Kempkensteffen C, Weikert S, Kollermann J, Krause H, Miller K, et al. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer 2006;95:1701-7.
29. Huser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, Giblett S, et al. MEK kinase activity is not necessary for Raf-1 function. EMBO J 2001;20: 1940-51.
30. Liu CY, Lee CF, Hong CH, Wei YH. Mitochondrial DNA mutation and depletion increase the susceptibility of human cells to apoptosis. Ann N Y Acad Sci 2004;1011:133-45.
31. Dangles-Marie V, Pocard M, Richon S, Weiswald LB, Assayag F, Saulnier P, et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res 2007;67:398-407.
32. Zeitlin BD, Joo E, Dong Z, Warner K, Wang G, Nikolovska-Coleska Z, et al. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res 2006;66:8698-706.
33. Brummer T, Naegele H, Reth M, Misawa Y. Identification of novel ERKmediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene 2003;22:8823-34.
34. Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010;102:1724-30.
35. Ritt DA, Monson DM, Specht SI, Morrison DK. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol 2010;30:806-19.
36. Shang T, Joseph J, Hillard CJ, Kalyanaraman B. Death-associated protein kinase as a sensor ofmitochondrialmembrane potential: role of lysosome in mitochondrial toxin-induced cell death. J Biol Chem 2005;280: 34644-53.
37. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3.
38. Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 2012;31: 446-57.
39. Abraham D, Podar K, Pacher M, Kubicek M, Welzel N, Hemmings BA, et al. Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. J Biol Chem 2000;275:22300-4.
40. Verschoor ML, Ungard R, Harbottle A, Jakupciak JP, Parr RL, Singh G. Mitochondria and cancer: past, present, and future. Biomed Res Int 2013;2013:612369.
41. Dykens JA, Marroquin LD, Will Y. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev Mol Diagn 2007;7: 161-75.
42. Fulda S, Galluzzi L, KroemerG. Targetingmitochondria for cancer therapy. Nat Rev Drug Discov 2010;9:447-64.
43. Smith RA, Murphy MP. Mitochondria-targeted antioxidants as therapies. Discov Med 2011;11:106-14.
44. Goto H, Takahashi H, Fujii H, Ikuta K, Yokota S. N-(4-Hydroxyphenyl) retinamide (4-HPR) induces leukemia cell death via generation of reactive oxygen species. Int J Hematol 2003;78:219-25.
45. Cao J, Xu D, Wang D, Wu R, Zhang L, Zhu H, et al. ROS-driven Akt dephosphorylation at Ser-473 is involved in 4-HPR-mediated apoptosis in NB4 cells. Free Radic Biol Med 2009;47:536-47.
46. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773: 1263-84.
47. TzivionG, Luo Z, Avruch J. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 1998;394:88-92.
48. Mielgo A, Seguin L, Huang M, Camargo MF, Anand S, Franovic A, et al. A MEK-independent role for CRAF in mitosis and tumor progression. Nat Med 2011;17:1641-5.
49. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40.